Trial Profile
Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas: Phase 1 Study
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Sep 2022
Price :
$35
*
At a glance
- Drugs Alpelisib (Primary) ; Trametinib (Primary)
- Indications Meningioma
- Focus Adverse reactions
- Acronyms ALTREM
- 29 Apr 2020 Planned End Date changed from 1 Jan 2022 to 1 Sep 2022.
- 29 Apr 2020 Planned primary completion date changed from 1 Jan 2022 to 1 Sep 2022.
- 29 Apr 2020 Status changed from not yet recruiting to recruiting.